Pyrimidinones as factor XIA inhibitors

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention al...

Full description

Saved in:
Bibliographic Details
Main Authors ORWAT, MICHAEL J, PABBISETTY, KUMAR BALASHANMUGA, EWING, WILLIAM R, DE LUCCA, INDAWATI, ZHU, YEHENG, PINTO, DONALD J.P, SMITH, LEON M. II, DILGER, ANDREW K, WANG, YU-FENG, CORTE, JAMES R, WEXLER, RUTH R, FANG, TIAN-AN, YANG, WU
Format Patent
LanguageChinese
English
Published 16.03.2023
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
Bibliography:Application Number: TW202211120670